Low and Declining Rate of 4-Class ARV Resistance Among Treatment-Experienced Patients in the EuResist Database

March 8-11, 2020; Boston, Massachusetts
Analysis of the EuResist database reveals prevalence and predictors of resistance to all 4 main ARV drug classes in treatment-experienced patients in Europe.
Format: Microsoft PowerPoint (.ppt)
File Size: 158 KB
Released: March 15, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
ViiV Healthcare

Related Content

Clinical Care Options (CCO) presents a woman’s perspective on managing the long-term effects of HIV, antiretroviral therapy, and aging

person default Anonymous Patient Released: January 11, 2022

From Dr. Fidelia Bernice and Clinical Care Options (CCO), expert commentary on managing polypharmacy in people with HIV

Fidelia Bernice, PharmD Released: January 6, 2022

Dr John Baxter and Clinical Care Options (CCO): Proviral genotyping may help to inform ART choice in patients with suppressed HIV-1 RNA, particularly if preexisting resistance is suspected

John D. Baxter, MD Released: December 29, 2021

Dr Karen Ha and Clinical Care Options (CCO): Data suggests there is a role for PIs in current practice for rapid initiation and experienced patients

Karen Ha, MD Released: December 27, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings